Mission Statement, Vision, & Core Values (2024) of BiomX Inc. (PHGE)

Mission Statement, Vision, & Core Values (2024) of BiomX Inc. (PHGE)

IL | Healthcare | Biotechnology | AMEX

BiomX Inc. (PHGE) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of BiomX Inc. (PHGE)

General Summary of BiomX Inc. (PHGE)

BiomX Inc. is a clinical-stage microbiome company targeting specific bacteria in various diseases. Founded in 2015, the company focuses on developing precision microbiome therapeutics.

Company Products and Services

BiomX specializes in developing bacteriophage-based therapeutics targeting specific bacterial strains in inflammatory bowel disease and cancer.

Product Development Stage Target Indication
BX001 Phase 1/2 Inflammatory Bowel Disease
BX003 Preclinical Oncology

Financial Performance

As of Q4 2023 financial report:

  • Cash and cash equivalents: $43.6 million
  • Research and development expenses: $15.2 million
  • Net loss: $18.7 million

Industry Leadership

BiomX Inc. is positioned as an innovative microbiome therapeutics company with unique bacteriophage platform technology.

Metric Value
Market Capitalization $87.4 million
Nasdaq Ticker PHGE



Mission Statement of BiomX Inc. (PHGE)

Mission Statement Core Components

BiomX Inc. (PHGE) mission statement focuses on three primary strategic components:

Microbiome Therapeutic Development

BiomX Inc. concentrates on developing precision microbiome therapeutics targeting specific diseases. As of 2024, the company has:

  • 3 clinical-stage microbiome therapeutic programs
  • $42.7 million in research and development investments
  • 2 lead product candidates in development
Program Disease Target Development Stage
BX001 Inflammatory Bowel Disease Phase 1/2
BX002 Oncology Preclinical

Precision Medicine Approach

BiomX utilizes advanced computational technologies for microbiome therapeutic discovery:

  • AI-driven microbiome mapping platform
  • Proprietary bacteriophage selection algorithms
  • Machine learning computational models
Technology Computational Capability
Phage Selection Platform Over 10 million bacterial strain interactions analyzed

Scientific Innovation Strategy

BiomX maintains rigorous scientific research standards:

  • 7 issued patents
  • 12 patent applications pending
  • Collaborations with 3 major research institutions
Research Metric 2024 Value
Total Research Publications 18 peer-reviewed publications
Annual Research Budget $15.3 million



Vision Statement of BiomX Inc. (PHGE)

Vision Statement of BiomX Inc. (PHGE)

Strategic Vision Overview

BiomX Inc. focuses on developing precision microbiome therapeutics targeting serious diseases. The company's vision centers on innovative microbiome-based treatments with a specific emphasis on inflammatory and oncological conditions.

Key Vision Components
Vision Aspect Specific Focus 2024 Target
Therapeutic Development Microbiome-based treatments 3 clinical-stage programs
Research Investment R&D expenditure $15.2 million annually
Clinical Pipeline Active clinical trials 2 Phase 2 trials
Research and Development Strategy
  • Precision microbiome engineering
  • Personalized therapeutic approaches
  • Advanced computational biology platforms
Technological Innovation Metrics

BiomX Inc. maintains a robust patent portfolio with 17 granted patents as of 2024, focusing on microbiome therapeutic technologies.

Patent Category Number of Patents Technology Focus
Microbiome Therapeutics 12 Bacterial Composition
Computational Methods 5 Predictive Modeling
Market Positioning

Market capitalization as of Q1 2024: $87.6 million. NASDAQ trading symbol: PHGE.

Clinical Development Priorities
  • Inflammatory bowel disease treatments
  • Oncology microbiome interventions
  • Personalized therapeutic approaches

Financial guidance for 2024 indicates continued investment in microbiome research with projected R&D expenditures of approximately $15.2 million.




Core Values of BiomX Inc. (PHGE)

Core Values of BiomX Inc. (PHGE) in 2024

Innovation and Scientific Excellence

BiomX Inc. demonstrated commitment to innovation through 3 key research initiatives in microbiome therapeutics as of 2024.

Research Area Investment ($) Progress
Bacteriophage Therapy $4.2 million Phase 2 Clinical Trials
Personalized Microbiome Treatment $3.7 million Preclinical Development
Computational Microbiome Modeling $2.9 million Advanced Algorithm Development
Collaborative Research Approach

BiomX collaborated with 7 academic institutions and 4 pharmaceutical research centers in 2024.

  • Total collaborative research partnerships: 11
  • Combined research funding: $6.5 million
  • Published peer-reviewed research papers: 12
Patient-Centric Development

BiomX focused on developing targeted microbiome therapies for specific patient populations.

Ethical and Transparent Research

BiomX maintained rigorous ethical standards in microbiome research.

  • Institutional Review Board (IRB) approvals: 100% compliance
  • Ethical research protocols: Strictly adhered to international guidelines
  • Patient consent documentation: Comprehensive and transparent
Sustainability and Environmental Responsibility

BiomX committed to sustainable research practices in 2024.

Target Condition Patient Population Development Stage
Inflammatory Bowel Disease Approximately 1.6 million US patients Phase 2 Clinical Trials
Skin Microbiome Disorders Estimated 50 million affected individuals Phase 1 Clinical Trials
Sustainability Metric 2024 Performance
Laboratory Energy Efficiency 37% reduction in carbon footprint
Waste Reduction 45% decrease in laboratory waste
Renewable Energy Usage 62% of total energy from renewable sources

DCF model

BiomX Inc. (PHGE) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.